524 related articles for article (PubMed ID: 11691810)
41. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
42. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
[TBL] [Abstract][Full Text] [Related]
43. Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy.
Yoshiura K; Nakaoka T; Nishishita T; Sato K; Yamamoto A; Shimada S; Saida T; Kawakami Y; Takahashi TA; Fukuda H; Imajoh-Ohmi S; Oyaizu N; Yamashita N
Clin Cancer Res; 2005 Nov; 11(22):8201-7. PubMed ID: 16299253
[TBL] [Abstract][Full Text] [Related]
44. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma.
Becker JC; Guldberg P; Zeuthen J; Bröcker EB; Straten PT
J Invest Dermatol; 1999 Dec; 113(6):1033-8. PubMed ID: 10594748
[TBL] [Abstract][Full Text] [Related]
45. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
46. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis.
Lucas S; De Smet C; Arden KC; Viars CS; Lethé B; Lurquin C; Boon T
Cancer Res; 1998 Feb; 58(4):743-52. PubMed ID: 9485030
[TBL] [Abstract][Full Text] [Related]
47. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J; Bystryn JC
Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
[TBL] [Abstract][Full Text] [Related]
48. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning.
Vaughan HA; St Clair F; Scanlan MJ; Chen YT; Maraskovsky E; Sizeland A; Old LJ; Cebon J
Cancer Immun; 2004 Jul; 4():5. PubMed ID: 15255672
[TBL] [Abstract][Full Text] [Related]
49. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
[TBL] [Abstract][Full Text] [Related]
50. Identification of selectively expressed genes and antigens in CTCL.
Hartmann TB; Mattern E; Wiedemann N; van Doorn R; Willemze R; Niikura T; Hildenbrand R; Schadendorf D; Eichmüller SB
Exp Dermatol; 2008 Apr; 17(4):324-34. PubMed ID: 17979976
[TBL] [Abstract][Full Text] [Related]
51. Optimized serological isolation of lung-cancer-associated antigens from a yeast surface-expressed cDNA library.
Kim MS; Choi HY; Choi YS; Kim J; Kim YS
J Microbiol Biotechnol; 2007 Jun; 17(6):993-1001. PubMed ID: 18050918
[TBL] [Abstract][Full Text] [Related]
52. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine.
Weber J; Salgaller M; Samid D; Johnson B; Herlyn M; Lassam N; Treisman J; Rosenberg SA
Cancer Res; 1994 Apr; 54(7):1766-71. PubMed ID: 7511051
[TBL] [Abstract][Full Text] [Related]
53. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
Höfs T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
[TBL] [Abstract][Full Text] [Related]
54. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity.
Kawakami Y; Suzuki Y; Shofuda T; Kiniwa Y; Inozume T; Dan K; Sakurai T; Fujita T
Pigment Cell Res; 2000; 13 Suppl 8():163-9. PubMed ID: 11041376
[TBL] [Abstract][Full Text] [Related]
55. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
56. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.
Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A
Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750
[TBL] [Abstract][Full Text] [Related]
57. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
58. Qualitative difference between the cytotoxic T lymphocyte responses to melanocyte antigens in melanoma and vitiligo.
Palermo B; Garbelli S; Mantovani S; Scoccia E; Da Prada GA; Bernabei P; Avanzini MA; Brazzelli V; Borroni G; Giachino C
Eur J Immunol; 2005 Nov; 35(11):3153-62. PubMed ID: 16224813
[TBL] [Abstract][Full Text] [Related]
59. Antimelanoma immunity in vitiligo and melanoma patients.
Juranic ZD; Stanojevic-Bakic N; Zizak Z; Babovic N; Radovic-Kovacevic V; Stanojkovic T; Dzodic R
Neoplasma; 2003; 50(4):305-9. PubMed ID: 12937846
[TBL] [Abstract][Full Text] [Related]
60. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis.
Hann SK; Kim JB
Yonsei Med J; 1995 Nov; 36(5):457-61. PubMed ID: 8546004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
